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Cerebrospinal fluid (CSF) levels of beta amyloid (Ab)
and tau isoforms are routinely used markers of Alzheimer’s
disease (AD) and at present recommended for inclusion in
research and clinical practice [1–3]. Concordant with these
recommendations are approaches to stratify subjects by
combinations of molecular markers, such as the amyloid/
tau/neurodegeneration (A/T/N) scheme [4]. These sugges-
tions originate from a currently intensively discussed
concept that neurodegenerative disorders should be defined
by their underlying molecular and cellular mechanisms,
while noticeable symptoms occur in later stages of disease
[5]. A common notion between facilitators and critics of
this concept is that current biomarkers, although powerful
for monitoring of specific pathological features, are still
insufficient to reflect the complexity of various neurodegen-
erative disorders [6]. AETIONOMY is a European, Innova-
tive Medicines Initiative–funded project dedicated to further
development of mechanism-based, molecular taxonomies of
AD and Parkinson’s disease (PD). One candidate mecha-
nismwithin this project was neuroinflammation, the reaction
of central nervous system (CNS) immune cells to patholog-
ical stimuli [7,8]: Neuroinflammation probably begins
during early presymptomatic stages with the sensing of
miss-folded and/or aggregated proteins like Ab or a-synu-
clein which represent danger-associated molecular patterns
and activate microglia and astroglia. Later, immune reac-
tivity propagates in response to neuronal death and the
respective damage signalling. Tracing biomarkers specific
for these processes is a prerequisite in the attempt to monitor
neuroinflammation as a taxonomy feature. Though many
typical proinflammatory proteins are hard to detect in the
CSF of dementia subjects, research has nonetheless led to
several immunity markers that can be reliably analysed
and therefore constitute reasonable candidates for functional
neuroinflammation panels [2,9–13]. This study aimed to
verify observations for 21 selected markers in CSF
samples derived from a multicenter cohort of 227 subjects
(nondemented/ND, mild cognitive impairment/MCI, AD
and idiopathic PD/IPD) provided by the AETIONOMY
network. All data acquired in this study are accessible
via the AETIONOMY knowledge base (https://data.
aetionomy.scai.fraunhofer.de/).
The panel consisted to one third of signalling molecules
such as cytokines/chemokines and other messengers
(YKL-40, TGF-b1, IP-10, MCP-1, MIF, MIP-1b), to one
third of soluble immune receptors and shedded receptor ec-
todomains (sIl-1RAcP, sAXL, sTyro3, sTREM2, sTNF-RI/
II, sICAM-1), and to one third of complement and innate im-
munity factors (CRP and the complement factors C1q, C3,
C3b, C4, B, H, and properdin). A brief overview of previous
findings for these markers including respective literature is
provided in Supplementary Table 1. This study furthermore
investigated critical covariates that have to be considered for
modelling of mechanisms, characterization of subject sub-groups, and potentially translation to clinical diagnostic or
interventional approaches.2. Methods
2.1. Study design and approval
An overview of the study design is given in
Supplementary Fig. 1. Samples and data were provided
from the cohorts/studies of AETIONOMY (https://www.
aetionomy.eu/en/vision.html), ICEBERG (https://icm-insti
tute.org/en/scientific-projects/), IDIBAPS (http://www.idi
baps.org/qui-som/en_index.html), and UKB (The university
clinic of Bonn Department of Neurodegenerative Diseases
& Geropsychiatry/Neurology, Germany, https://neurodeg.
uni-bonn.de/).
Subjects were recruited following local authorities’
ethical approval and by informed consent.
2.2. Sampling and preanalytical procedures
CSF samples were obtained by lumbar puncture per-
formed by trained medical personal following standardized
procedures and good clinical practice guidelines. Preanalyt-
ical sample handling procedures differed between AETION-
OMY/ICEBERG (protocol 1), IDIBAPS (protocol 2), and
UKB (protocol 3) by centrifugation, method of freezing,
type of polypropylene storage tubes, and time point of
freeze/thaw cycles within the procedure: Protocol 1 included
no centrifugation of samples, preparation of aliquots before
freezing, and freezing as well as storage in liquid nitrogen.
Protocol 2 included centrifugation at 2000 ! g for 10 mi-
nutes at 4C, followed by preparation of aliquots and
freezing and storage in a280C freezer. Protocol 3 included
snap-freezing in liquid nitrogen immediately after LP
without centrifugation, and subsequent storage in a 280C
freezer. Then, samples underwent one freeze-thaw cycle
for subfractionation into smaller aliquots. Independent of
origin, all samples had a total of 2 freeze-thaw cycles on
analysis.
2.3. Biomarker analysis
The AD standard biomarkers (beta-amyloid [Ab] 42,
total-tau [t-tau], and phospho-tau [p-tau]-181) were deter-
mined at IDIBAPS using Fujirebio GmbH INNOTEST as-
says and local cutoff values (Ab42, 550 pg/ml; t-tau, 450 pg/
ml; p-tau-181, 65 pg/ml; and the ratio Ab42/p-tau-181, 7.5).
For determination of immunity biomarkers, samples were
processed on ice until application to the assay. Samples
and calibrators were run in duplicates, and samples with a
duplicate coefficient of variance .15% were repeated. To
normalize for interrun variances, a pooled and aliquoted
CSF sample was run as an internal control on each assay
plate. Details on the assays used are found in
Supplementary Table 2. YKL-40 was analyzed at IDIBAPS
and all other markers at UKB/DZNE.
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The statistical workflow is depicted in Supplementary
Fig. 2. Data analysis and visualization were done using
Prism 7 (GraphPad Software Inc., La Jolla, CA) and IBM
SPSS Statistics 21 (IBM Corporation, Armonk, NY).
Nonparametric statistics were preferably used for group
comparisons (Kruskal-Wallis or Mann-Whitney U tests)
and correlation matrix calculation (Spearman correlation
analysis). For parametric tests such as ANCOVA and partial
correlation, log-transformed values were used. Covariance
analysis was done stepwise including first all covariates
and in the next step only those significant were included.
Distribution of sex and APOE genotype was tested using
Pearson’s chi-squared test. Significance level was defined
as a5 0.05, and the Bonferroni method was used to control
for multiple testing of the 21 immunity markers and pairwise
comparisons in multigroup tests. Comparison of linear
regression functions was calculated using the method
described by J.H. Zar [14].3. Results
3.1. Normalization of center-specific effects
Demographic data were heterogeneous between the
included cohorts/studies, and subject groups were obtained
from different centres using different preanalytical protocols
and recruiting from different populations (for detailed
descriptive statistics, see Supplementary Tables 3-6). We
therefore addressed potential influence of center-specific ef-
fects and found 10 markers affected (Supplementary
Table 7): Samples obtained from IDIBAPS (centre 1) had
lower values of sTREM2, IP-10, MCP-1, MIF, C1q, C4, fac-
tor B, and properdin than those from AETIONOMY/
ICEBERG (centre 2). By contrast, C3 and C3b levels were
higher for samples from IDIBAPS compared to those from
AETIONOMY/ICEBERG (Supplementary Fig. 3). Values
of affected markers were adjusted using normalization fac-
tors calculated from the median values within the ND sub-
jects dichotomized by centre of origin. Effects observed
for these normalized values were reflected by trends in the
nonnormalized data dichotomized by centre.3.2. Influence of age, sex, and APOE genotype
Correlation analysis (Fig. 1) showed positive correlations
of age and immune biomarker levels for most markers. Five
markers differed significantly by sex, of which the comple-
ment factors H and properdin were robustly elevated in
males (details in Supplementary Table 8). A total of 9
markers differed between APOE ε4–positive and APOE
ε4–negative individuals (Supplementary Table 8). All these
markers were slightly higher in APOE-positive individuals
with the exception of CRP, which was significantly lower
in APOE ε4–positive individuals.3.3. Clinical and pathological stratification
When stratified by clinical diagnosis, complement factors
C1q, C3, and B as well as sTREM2 and IP-10 differed signif-
icantly after adjustment for covariates and multiple testing
(see Supplementary Table 9 for extensive description and
weaker trends). In no comparison, the IPD group differed
from the ND group, but MCI and/or AD groups showed dif-
ferences compared to ND and/or IPD groups. Next, we used
pathological AD biomarker levels for stratification ap-
proaches: First, by use of single markers, second, by use
of the Ab42/p-tau-181 ratio, and finally, by use of the A/T
scheme combining amyloid and t-tau classification
(Supplementary Tables 10-14). Observed effects were
highly redundant between use of t-tau or p-tau-181 as strat-
ification variables. Most informative and congruent with
single-marker-based approaches was stratification by A/T
scheme (Figs. 2 and 3). Significant markers can be divided
into 3 groups: First, those influenced primarily by amyloid
but not tau showing decreased median in amyloid-positive
groups (only complement C3). Second, those primarily
influenced by tau but not amyloid with increased median
levels in tau-positive groups (YKL-40, MIF, sTNF-RI,
sTNF-RII, sTREM2, C1q, C4). Third, those with potential
influence of both amyloid and tau, resulting in reduced me-
dian in the A1T- group compared to A- T- and A1T1, but
equal or slightly higher median in A1T1 compared to A-T-
(YKL-40, sTyro3, sAXL, sICAM-1, C3b, factor H). This
observation, however, is limited by a low number of only 9
subjects within the A- T1 group.
3.4. Sex-specific effects on pathology-based comparisons
Sexwas a strong covariate of several complement factors,
YKL-40 and TGF-b1 in all comparisons that were based on
pathological AD marker levels: When stratified by both sex
and pathological amyloid, YKL-40 and the complement fac-
tor H showed more pronounced effects in male than in fe-
male subjects (Supplementary Table 15). In similar
manner, when combining stratification by sex with tau pa-
thology, the complement factors C1q, C4, and B as well as
TGF-b1 were significantly influenced by both: The elevation
of these proteins in tau-positive subjects (either t-tau or p-
tau-181) was more pronounced in males than in females
(Supplementary Table 16).
3.5. Age-dependent pathological trajectories
Given that many of the pathology-related observations
were significant, but of small effect size, and the fre-
quency of age as covariate, we plotted immune marker
levels against age dichotomized by pathological versus
nonpathological amyloid or t-tau values (Figs. 4 and 5).
For all markers significantly correlated to both aging
and the pathology marker, we compared intercept and
slope of the respective linear regression models
(Supplementary Tables 17 and 18). In general, these
Fig. 1. Correlation matrix of immune markers, ADmarkers, and clinical features. Results of Spearman correlations visualized as heat map: Lower left part5 P
values; upper right part 5 r-values. Storage time applied only to the 21 markers investigated in this study. (1-3) Immune markers, AD markers, and clinical
features correlated against each other, respectively. (4) Immune markers versus AD markers. (5) Immune markers versus clinical features. (6) AD markers
versus clinical features. Within the clinical features, only age, years from onset, and MMSE were available for all groups of subjects. All other clinical features
were available for IPD subjects only. Abbreviations: AD, Alzheimer’s disease; FAB, Frontal Assessment Battery; HADS, Hospital Anxiety and Depression
Scale; IPD, idiopathic Parkinson’s disease; MDS-UPDRS, International Parkinson and Movement Disorder Society Unified Parkinson’s Disease Rating Scale;
MMSE, Mini–Mental State Examination; MOCA, Montreal Cognitive Assessment; NMSS, Non-Motor Symptoms Scale.
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trajectory, and intercept, but not slopes of theses trajec-
tories differed significantly. Where available, data were
compared between this study and the previously published
UKB data set. YKL-40 was the strongest and most repro-
ducible correlate to amyloid and age and on lower trajec-
tory in amyloid positive in both data sets. Age trajectories
dichotomized by t-tau were more pronounced: In both datasets, levels of YKL-40, sTREM2, complement C1q, and
MIF were on elevated tracks. MCP-1 and sICAM-1 had
elevated intercepts only within the AETIONOMY/
ICEBERG/IDIBAPS data, but not in the UKB data set.
Of the markers available within the AETIONOMY/
ICEBERG/IDIBAPS cohorts only, sAXL, sTyro3, comple-
ment factors C3 and C4, TGF-b1, and the soluble TNF re-
ceptors I and II had elevated trajectories. In comparison,
Fig. 2. Chemokines and soluble receptors stratified by A/T scheme. Biomarker values of chemokines and soluble receptors compared by A/T scheme: amyloid
and t-tau nonpathological (A- T-); amyloid nonpathological, t-tau pathological (A- T1); amyloid pathological, t-tau nonpathological (A1T-); amyloid and t-tau
pathological (A1T1). Plots show individual data points, median, and interquartile range for the 8 most significant markers. Bar graphs indicate significant
Bonferroni-adjusted pairwise comparisons (* pAdj.  0.05; ** pAdj.  0.01; *** pAdj.  0.001). See Supplementary Table 14 for further details on statistics
and markers not depicted in the figure. (A) YKL-40, (B) MIF, (C) Tyro3, (D) AXL, (E) sTNF-RI, (F) sTNF-RII, (G) sICAM-1, (H) sTREM2.
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Fig. 3. Complement factors stratified by A/T scheme. Complement factor level values compared by A/T scheme: amyloid and t-tau nonpathological (A- T-);
amyloid nonpathological, t-tau pathological (A- T1); amyloid pathological, t-tau nonpathological (A1 T-); amyloid and t-tau pathological (A1 T1). Plots
show individual data points, median, and interquartile range. Bar graphs indicate significant Bonferroni-adjusted pairwise comparisons (* pAdj.  0.05; **
pAdj.  0.01; *** pAdj.  0.001). See Supplementary Table 14 for further details on statistics and markers not depicted in the figure. (A) C1q, (B) C3, (C)
C3b, (D) C4, (E) Factor H.
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sTNF-receptors I and II, and MIF. As visualized by the
95% confidence intervals within the plots, this analysis
was limited by increasing degrees of uncertainty for the
youngest and oldest areas on the age axis.Not all markers that correlated to both pathology and ag-
ing showed such additive effects when stratifying trajec-
tories: For MIP-1b and complement C3b, there was no
difference in age-dependent linear models when stratified
by pathology biomarker levels.
Fig. 4. Pathological aging signatures comparable between previous and current subject cohorts. Immune biomarker values were dichotomized based on path-
ological/nonpathological amyloid or t-tau and plotted against subject age (see Supplementary Tables 17 and 18). Results are compared between the current
AETIONOMY/ICEBERG/IDIBAPS and the previously analysed UKB cohort. The figure depicts results for 4 markers in which these trajectories differed,
and which were available in both data sets: (A) YKL-40 dichotomized by amyloid. (B–E) YKL-40, MIF, sTREM2, and C1q dichotomized by t-tau.
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Fig. 5. Pathological aging signatures within the AETIONOMY/ICEBERG/IDIBAPS cohort. Immune biomarker values were dichotomized based on patholog-
ical/nonpathological t-tau and plotted against subject age (see Supplementary Tables 17 and 18). Results are shown for the 4 most significant markers available
in the current AETIONOMY/ICEBERG/IDIBAPS cohort only. The figure depicts results for (A) sAXL, (B) sTYro3, (C) sTNF-RI, (D) sTNF-RII.
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independent of aging
The strongest correlations of immune markers (in partic-
ular, sAXL, sTYro3, sTNF-RI, sTNF-RII, sTREM2, and
MIF) to clinical features were those with H&Y staging
within the IPD group (Fig. 6). Further important correlates
of the H&Y stage were age and tau isoforms, which were
also co-correlated to all the 6 relevant immune markers.
When adjusting the 6 correlations for aging by partial corre-
lation analysis, the correlations were robust though strength
of correlation weakened (Supplementary Table 18).
Compared by the linear functions of these correlations, t-
tau showed the strongest increase throughout the H&Y
stages, with successively weaker effects of the respective im-
mune markers.4. Discussion
4.1. Key findings
This study provided three main findings: First, a high
reproducibility of effects observed for the selected markers
(see Section 4.2). Second, the predominant association of
immunity markers with pathological levels of amyloid
or—to a greater extent—neuronal degeneration (as
measured by t-tau and p-tau-181) independent of diagnosis.
These results are supportive of the use of mechanism-based
disease taxonomies in addition to clinical features. Third,
that ageing is a major covariate of immunity markers (seeSection 4.3) and therefore constitutes a potentially powerful
component of models to improve applicability of these
markers in medical practice or studies.4.2. Reproducibility of findings
For the purpose of conciseness, an overview of previous
findings for comparison, including the respective literature,
is given in Supplementary Table 1.
YKL-40: Within this study, YKL-40 was not influenced
by centre, storage time, and APOE genotype and only
partly by sex, while age was a significant covariate in all
comparisons. It was replicated to be associated with clin-
ical diagnosis, pathological biomarkers, and in IPD with
H&Y staging. Among these, the relation to tau isoforms
was the strongest. The association to MCI or AD diagnosis
was less strong in this study, and elevation in amyloid pos-
itive individuals was probably driven by the amyloid- plus
tau-positive subpopulation. When plotted against age,
YKL-40 was on lower trajectory in amyloid positive in
both the AETIONOMY/ICEBERG/IDIBAPS as well as
the UKB data set, though elevated in amyloid-positive sub-
jects when not adjusted for age. Furthermore, YKL-40
levels were on a (more pronounced) higher trajectory in
tau positive. This could be in line with previous reports
of potential bidirectional regulation of YKL-40 throughout
disease, though more research will be necessary for valida-
tion [15].
MIF: Of the other cytokines or growth factors investi-
gated, MIF showed the strongest effects, in particular in its
Fig. 6. Correlations of immune markers and t-tau with Hoehn & Yahr stage in IPD. Correlations in figure were robust against aging as covariate of the Hoehn &
Yahr stage (see Supplementary Table 19). Individual values with linear correlation function and 95% confidence intervals. Results are shown for the IPD group
only: (A) sAXL, (B) sTYro3, (C) sTNF-RI, (D) sTNF-RII, (E) sTREM2, (F) MIF, (G) t-tau. To compare effect strength of the correlations, relative functions of
these markers were plotted together against H&Y stage (H). Abbreviation: IPD, idiopathic Parkinson’s disease.
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H&Y stage similar to YKL-40. MIF is known to be released
upon brain injury, and a similar reaction might be triggered
in neurodegeneration. The resulting proinflammatory signal-
ling might be aggravating the disease and even increase key
pathological hallmarks such as tau hyperphosphorylation
[16]. Nonetheless, MIF is a multifunctional protein that
has cytokine and enzyme properties, is involved in wound
healing processes, and can act as a neurotrophic factor[17,18]. An advantageous aspect of MIF as biomarker is
that it is well detectable in CSF, in contrast to many of its
downstream signal mediators.
Soluble receptors: Like MIF and YKL-40, soluble TAM
and TNF receptors as well as sTREM2 were reproducibly
associated with tau and ageing. For soluble TAM receptors,
there might be additional influence of amyloid similar to that
observed for YKL-40. These findings are well in line with
previous observations. Noteworthy, the ectodomains of these
F. Brosseron et al. / Alzheimer’s & Dementia- (2019) 1-1310receptors are released upon cleavage by sheddases like
ADAM10 and ADAM17, and conditions of shedding as
well as the function of the soluble ectodomains are incom-
pletely understood [19–22]. The shedded receptors can
have antagonistic function or act as signal mediators.
Hence, closer understanding of the age- and
neurodegeneration-reactive increase of soluble receptor
levels will be required to understand the potential for inter-
vention in this process.
For the soluble coreceptor sIL-1RAcP, we observed
weaker effects associated with diagnosis or amyloid load
but did not confirm previous results of higher levels in IPD
previously reported [9].
Complement factors: In this study, C1q was associated
with pathological tau and ageing less dependent of amyloid
pathology, while C3, C3b, and factor H were related to
pathological amyloid levels rather than tau pathology.
Hence, biomarker levels of these markers might depend
on different mechanisms in different stages of disease. Crit-
ical covariates were age and sex (confirmative with many
studies), but in contrast to a study by Bonham et al. [23]
not the APOE status. As described in previous studies,
observed effect sizes were small and accompanied by
high interindividual variance. Furthermore, differences be-
tween antibodies or differing proteomics detection tech-
niques might lead to detection of different isoforms,
increasing heterogeneity. Although it is still not entirely
clear how exactly complement mechanisms in the degener-
ating CNS translate into CSF biomarker levels, further
investigation and standardization—in particular for C3
and C1q—could help to monitor complement system acti-
vation in AD and PD.
CRP was lower in APOE ε4–positive individuals and
robustly associated with amyloid load, but not diagnosis or
tau pathology, as described in our previous study [9].4.3. Influence of biological confounders
Agewas the most striking covariate throughout this study.
It was positively correlated to levels of most immune pro-
teins and—naturally—with severity of disease in AD and
PD as measured by AD biomarkers or H&Y stage. Although
a critical confounder, associations found for immune
markers and pathological features were robust against
ageing. Combined stratification for ageing and pathology
markers showed modified aging trajectories and could
significantly improve the power of immune markers, while
unadjusted age influence otherwise can obscure effects
caused by pathological processes.
Sex was a significant confounder predominantly of com-
plement factors, but also TGF-b1 and YKL-40 in some tests.
These were elevated in male compared to female donors,
which mixed with effects caused by pathology in similar
manner as for ageing. Findings for complement factors
were also more pronounced in males than in females. Inmouse models and human serum, complement activity is
lower in females compared to males [24,25]. Intriguingly,
AD is more prevalent in females, while PD is more
prevalent in males [26]. Therefore, in particular for the com-
plement system, but also for other markers, sex should be
considered as important as age as potential confounder.
Positivity for one or two APOE ε4 alleles was associated
with slightly higher levels of many cytokines or soluble re-
ceptors (in contrast to complement factors). When
comparing pathological groups, however, APOE genotype
was less frequently significant compared to age or sex,
though consistently observed as highly influential covariate
of CRP. The latter finding is of good congruence with our
previous findings [9].4.4. Limitations
When analyzing data from this multicentre collection of
samples, we found differences between levels of sTREM2,
chemokines, and 6 complement factors that were apparently
derived from center-specific factors. To address this issue,
we assumed that biomarker levels of nondemented subjects
matched by age, genotype, storage time, and sex should be
within the same median range, and to calculate normaliza-
tion factors on this basis. Although this strategy led to
reasonable results, it does not allow for conclusions on the
origin of observed variances. Potentially, differences in pre-
analytical protocols between the centres could be causative
for the observed discrepancies, as the impact of preanalytical
factors on biomarker levels is acknowledged well in research
and assay manufacturer’s instructions for standard AD
markers in CSF and for immune markers in blood samples
(though barely investigated for immune markers in CSF)
[27,28]. This would indicate that standardization and
characterization of preanalytical confounders is of
importance not only for the routinely used amyloid or tau
isoforms but also for several immune markers frequently
studied in CSF. Yet, this work did not include systematic
assessments of preanalytical factors, and observed
differences could also be caused by population-based factors
that differed between the centres but were not tracked in this
study.
Aside of these centre-specific effects, this study had other
limitations. While sample size enabled groupwise compari-
sons or combinations of up to two variables (e.g., tau and ag-
ing), further subdivision of the overall cohort led to low
numbers of samples that would not allow for reliable evalu-
ation. Yet, the results of this study suggest that the discrim-
inative power of immune biomarkers in neurodegeneration
could be enhanced when combining multiple covariates
such as age and sex and stratifying subjects by combinatorial
biomarker approaches, such as in the A/T scheme. This
concept could only be verified in drastically larger cohorts
of subjects with sufficiently large numbers of CSF samples.
Another limitation to the interpretation of our results is that
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work are also found in peripheral blood in higher concentra-
tions than in CSF. Disruption of the blood-brain barrier dur-
ing aging and in CNS neurodegenerative/neuroinflammatory
diseases might lead to infiltration of peripheral immune cells
and diffusion of proteins from the blood into the CSF
[29,30]. Within this study, there were no measures for
blood-brain barrier integrity. Hence, the data do not allow
for a calculation of the influence of cells or proteins of pe-
ripheral origin on observed CSF biomarker measures.
Mini–Mental State Examination was the only neurocog-
nitivemeasure included in this study and showed several sig-
nificant, but weak correlations to immunity markers, thereby
limiting comparability to studies on interaction with cogni-
tive performance.4.5. Outlook
With YKL-40 and sTREM2, astroglial or microglial
biomarkers emerged, which were found to be associated
with AD and its pathological hallmarks in multiple
studies [2,9,10,31–34]. Several further immunity markers
investigated in this work also showed reproducible
effects, though more data are required for validation.
However, discriminatory power of these markers is still
limited when comparing subjects based on diagnosis only
[9]. In addition, findings still vary in details such as time
course of changes and strength of interaction with amyloid
or tau, respectively. Findings within this study underlined
the importance of standardization of procedures and strati-
fication for pathological subgroups and covariates. Most
striking were differences in age-dependent trajectories of
immune markers between tau-positive or -negative individ-
uals that were independent of clinical diagnosis of MCI,
AD, or PD. These proteins might present a pattern of
response to neurodegeneration present in different disor-
ders, proofing the concept to characterize subjects not
only symptomatic, but also by molecular/cellular taxon-
omies of disease. Furthermore, they could serve as readout
markers in interventional studies targeting neuroinflamma-
tion, but only when important confounders such as age or
sex are considered. In conclusion, future study designs
should enable such multivariate stratification of cohorts
to increase the discriminatory power of immunity markers
as this could be decisive for the applicability of these bio-
markers in the clinical context.Acknowledgments
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1. Systematic review: This study was designed based on
previous articles and PubMed literature search. It
was further embedded in the European, Innovative
Medicines Initiative project AETIONOMY that
facilitated interdisciplinary exchange between clini-
cians and researchers.
2. Interpretation: In a multicenter cohort, the study veri-
fied many previous findings for immunity-associated
biomarkers in cerebrospinal fluid. However, it also
showed that immune marker levels were associated
with severity of neurodegeneration (reflected by tau
levels) rather than clinical diagnosis of Alzheimer’s
disease or Parkinson’s disease. Age and sex of pa-
tients, but also center-specific factors, had strong
influence on the immunity markers.
3. Future directions: (A) To investigate and standardize
preanalytical factors not only for amyloid and tau but
also for immunity biomarkers in cerebrospinal fluid.
(B) To characterize immune biomarker levels in
dependence of pathology markers plus aging, sex,
and genetic factors in large cohorts. (C) To charac-
terize patients not only by symptoms but also by mo-
lecular markers representative of multifactorial brain
pathologies.References
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